12/12/2024
In 2024, the biotherapeutics industry made significant progress in transforming disease treatment, one example being the landmark approval of CASGEVY®, the first cell-based gene therapy for the treatment of transfusion-dependent beta-thalassemia.
In this Q&A, Dr. Francisca Neethling, Head of Biotherapeutic Services at Eurofins Discovery, shares the highs and lows of the past year, the team’s successes and what to expect in 2025. Read it now: https://app.scientist.com/blog/2024/12/12/the-year-in-review-biotherapeutics-in-2024-and-a-look-ahead-to-2025
